TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06915233: A Prospective, Open-label, Randomized, Concurrent Active-controlled, Longitudinal, Multicenter, Phase 3 Clinical Study of the Safety and Efficacy of MACI in Patients With Symptomatic Chondral or Osteochondral Lesions of the Talus (MASCOT)

Sponsor: Vericel Corporation · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 309 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$7,684,472

Rescue Site Savings

+$5,091,552

Unlock Full NCT06915233 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06915233 Rescue Dossier →